Rudower Chaussee 29
Dr. Udo Baron
+49 (0) 30 6392 3475
+49 (0) 30 6392 3479
Using a novel molecular diagnostics technology, Epiontis offers an immune cell monitoring service as well as customized development of epigenetic assays.
Epiontis' epigenetic assay format allows the identification and quantification of any cell type with accuracy and technical ease. Our assays are used as a quality control tool to ensure purity of cellular samples in e.g. Cell Therapy and Regenerative Medicine.
Another broad field of use is the monitoring of immune cells in research and clinical studies in autoimmune and infectious disease or cancer. Here, we offer a portfolio of established assays for immune cells. Examples include diagnostic assays for regulatory T cells (Treg) and tumor infiltrating lymphocytes with many other epigenetic assays under development.
Dr. Olek is the founder and CEO of Epiontis. He received a B.Sc. from the Imperial College of Science, Technology, and Medicine in London, UK and a Ph.D. in Biochemistry from the University of Heidelberg in Germany. He did postdoctoral research at the University of Heidelberg and at R.W. Johnson Pharmaceutical Research Institute in San Diego, USA. He is co-inventor on the patent forming the basis of the intellectual property of Epiontis.